19646-07-2

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dichloro-5-methoxypyrimidine is used as a key intermediate for the preparation of heteroarylpiperazine derivatives, which are important in the treatment of Alzheimer's disease. These derivatives have shown potential in modulating the neurochemical processes associated with the disease, thereby offering therapeutic benefits to patients suffering from cognitive decline and memory loss.

InChI:InChI=1/C5H4Cl2N2O/c1-10-3-2-8-5(7)9-4(3)6/h2H,1H3

Upstream product

• 6623-81-0 5-Methoxypyrimidine-2,4(1H,3H)-dione 
• 6623-81-0 5-methoxyuracil 

Downstream Products

• 98021-95-5 2-Chloro-4-hydrazino-5-methoxy-pyrimidine 
• 1042434-81-0 2-{[2-chloro-5-(methoxy)-4-pyrimidinyl]amino}benzamide 
• 99979-77-8 2-chloro-5-methoxypyrimidin-4-amine 
• 1313718-44-3 4-[5-methoxy-2-(3-nitrophenyl)pyrimidin-4-yl]morpholine 
• 1313718-69-2 4-(5-methoxy-4-morpholin-4-ylpyrimidin-2-yl)-2-nitrophenylamine 
• 1313718-71-6 4-(5-methoxy-4-morpholin-4-ylpyrimidin-2-yl)benzene-1,2-diamine 
• 1245506-61-9 2-chloro-5-methoxy-4-methylpyrimidine 
• 1269626-31-4 N-benzyl-2-chloro-5-methoxy-pyrimidin-4-amine 
• 1269626-28-9 (2-chloro-5-methoxy-pyrimidin-4-yl)-ethyl-amine 
• 878650-31-8 methyl 2,6-dichloro-5-methoxy-pyrimidine-4-carboxylate 
• 1126320-49-7 methyl 6-amino-2-chloro-5-methoxy-pyrimidine-4-carboxylate 
• 1427295-99-5 C₁₆H₁₇N₇O₃ 
• 1427296-00-1 C₁₆H₁₉N₇O 
• 695-85-2 4-chloro-5-methoxy-pyrimidine 

Relevant academic research and scientific papers

Experimental measurement and correlation of the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane at temperatures between (295 and 320) K

The solid-liquid equilibrium of 2,4-dichloro-5-methoxypyrimidine was first determined in this article. Using a laser monitoring observation technique, the solubilities of 2,4-dichloro-5-methoxypyrimidine in ethyl ethanoate, methanol, ethanol, acetone, tetrachloromethane, and heptane have been determined experimentally from (295.60 to 316.39, 302.37 to 316.95, 299.44 to 316.61, 297.35 to 311.37, 298.60 to 312.15, and 298.10 to 320.08) K, respectively. The results are correlated with λ-h equation and Apelblat equation. The calculated results show that the correlation of the Apelblat model for six measured systems has less deviation than that of the λ-h equation.

Preparation method of 2-chloro-5-methoxypyrimidine

The invention relates to the field of compound preparation methods, and in particular relates to a preparation method of 2-chloro-5-methoxypyrimidine, which is prepared by taking methyl methoxyacetateas a raw material. The product prepared by the preparation method has high purity, the catalyst and the solvent can be recycled, the reaction is mild, the control is easy, and the method is suitablefor industrial production.

Solvent-free or low-solvent large-scale preparation of chloropyrimidine and analogues

Chloropyrimidine or other N-containing aromatic heterocyclic analogues can be efficiently prepared from the corresponding hydroxylated precursors under solvent-free or low-solvent conditions with equimolar or less chlorinating reagents. This high-yielding protocol allows successful preparations of multigram and kilogram batches of these important synthetic intermediates.

NOVEL PYRIMIDINE COMPOUNDS AS MTOR AND P13K INHIBITORS

The present invention relates to pyrimidine compounds of formula (I): which are useful in treating mTOR kinase- or PI3K kinase-related diseases.

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV

The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.

Falcipain inhibitors: Optimization studies of the 2-pyrimidinecarbonitrile lead series

Falcipain-2 and falcipain-3 are papain-family cysteine proteases of the malaria parasite Plasmodium falciparum that are responsible for host hemoglobin hydrolysis to provide amino acids for parasite protein synthesis. Different heteroarylnitrile derivatives were studied as potential falcipain inhibitors and therefore potential antiparasitic lead compounds, with the 5-substituted-2- cyanopyrimidine chemical class emerging as the most potent and promising lead series. Through a sequential lead optimization process considering the different positions present in the initial scaffold, nanomolar and subnanomolar inhibitors at falcipains 2 and 3 were identified, with activity against cultured parasites in the micromolar range. Introduction of protonable amines within lead molecules led to marked improvements of up to 1000 times in activity against cultured parasites without noteworthy alterations in other SAR tendencies. Optimized compounds presented enzymatic activities in the picomolar to low nanomolar range and antiparasitic activities in the low nanomolar range.

ANTHRANILAMIDE INHIBITORS OF AURORA KINASE

The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R1, R2, R3, R4, r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.